ClinicalTrials.gg
Status unknownNCT03270735Updated Sep 1, 2017

A Clinical Study to Evaluate the Efficacy and Safety of Hemocoagulase Injection

A Phase 4 interventional study of Snake venom thrombin (Treatment) and Placebo in Hemoptysis, sponsored by Lee's Pharmaceutical Limited. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-09-01.

Sponsored by Lee's Pharmaceutical Limited · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jun 2017), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a multi-centre, randomised, double blind, placebo controlled clinical study which is designed to evaluate the efficacy and safety of hemocoagulase in the treatment of moderate to severe hemoptysis.

02

Conditions studied

  • Hemoptysis

Browse trials for

03

In context

Hemoptysis

37 studies on the registry are indexed under Hemoptysis; 6 are open to participants now.

This study's planned enrollment of 100 is above the median of 73 across 20 interventional studies indexed under Hemoptysis.

Browse Hemoptysis studies →

Lead sponsor

Lee's Pharmaceutical Limited is the lead sponsor of 74 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-75 years;
  • Hemoptysis >=100 mL within 24 hours;
  • Bronchiectasis diagnosed by chest high resolution CT;
  • Patient, family or guardian is willing to sign the form.

Exclusion criteria

Exclusion Criteria:

  • With severe hepatic or renal insufficiency, >3 , \<30 mL/min or serum creatinine ≥200 µmol/L or ≥2.5 mg/dL;
  • Uncontrollable hypertension (SBP>180mmHg or DBP>110mmHg) or hypotension shock (SBP\<90 mmHg) at randomization;
  • History of thrombosis, patients who have undergone thrombosis, or who have severe hematologic diseases;
  • Patient with bleeding caused by DIC or vascular disease;
  • Patient with coagulation dysfunction

    1. >2
    2. Patient with abnormal coagulation function or other bleeding disease (including clinical congenital bleeding disorders, such as von Willebrand disease or acquired hemophilia; hemorrhagic disease; and significant unexplained hemorrhagic disease)
    3. count \<100×109 /L;
  • known allergic to aspirin, clopidogrel, heparin, snake venom blood clotting enzyme, or any component in the study drug allergy or allergic constitution;
  • Women who are pregnant or lactating and women of child-bearing agewho do not take reliable measures;
  • Patients who are or are planning to participate in other clinical trials during the study period;
  • Within 72 hours before using the following products including Hemocoagulase For Injection (邦亭®), injection spearhead haemocoagulase (巴曲亭®), Haemocoagulase Agkistrodon for Injection (苏灵®), Hemocoagulase Atrox for Injection (立止血®), leaf pigment or other hemostatic agents;
  • of less than 3 months;
  • Any other patients who have been judged unfit to participate in this clinical study, including those who are unable or unwilling to comply with the protocol requirements;
  • Patients who had participated in other clinical studies within three months prior to the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Treatment

    Snake venom thrombin

    Drug: Snake venom thrombin (Treatment)

  • Placebo comparator
    Placebo

    Snake venom thrombin simulant

    Drug: Placebo

Interventions

  • DrugSnake venom thrombin (Treatment)

    Snake venom thrombin

    Also known as: Snake venom thrombin

  • DrugPlacebo

    No snake venom thrombin

    Also known as: Snake venom thrombin simulant

06

What researchers measure

Primary outcomes

  1. AEs and SAEs

    The incidence of AEs and SAEs

    Time frame: 7 days

Secondary outcomes

  1. Effective rate of treating hemoptysis

    Effective rate of treating hemoptysis 72 hours after administration

    Time frame: 72 hours

07

Study locations

1 of 1 sites recruiting
  • Fuwai Hospital Chinese Academy of Medical Sciences
    Beijing, 100037, China
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 1, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03270735
Collaborators
Zhaoke Pharmaceutical (Hefei) Company Limited
Responsible party
Sponsor
First posted
Sep 1, 2017
Start date
Jun 6, 2017
Primary completion
Jun 2018 (estimated)
Completion
Dec 2018 (estimated)
Last update
Sep 1, 2017

Study contacts

Nan Yang, MD, PhD
Contact
nancy.yang@leespharm.com
852-23146533

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion